Objectives: The prescribing of oral chemotherapy agents previously available only in the intravenous formulation, such as capecitabine, has afforded many benefits including reduced administration costs and improved patient acceptability. However, it has introduced the new challenge of ensuring patient adherence to therapy. It is therefore necessary to quantify adherence, and with a view to improving services, explore factors that may impact on medication taking behavior.

This meta‐analytic review examines the most fundamental question for disclosing evidence during suspect interviews: What are the effective options for when to disclose the available evidence? We provide an update to Hartwig and colleagues (2014) meta‐analysis of the efficacy of the late and early disclosure methods on eliciting statement‐evidence inconsistencies from guilty and innocent suspects. We also extend these analyses to include studies comparing gradual disclosure to early and late disclosure when interviewing guilty suspects. Finally, we test whether a gradual disclosure leads to greater provision of novel investigative information when interviewing guilty suspects. Overall, we find that guilty suspects provide more statement‐evidence inconsistencies than innocent suspects, and that both a late and gradual disclosure result in more statement‐evidence inconsistencies than the early disclosure when interviewing guilty suspects. However, there are indications of small study effects that warrant considerable caution when interpreting the size of some of the identified effects.